不同类别生物制剂治疗银屑病可降低外周型与中轴型银屑病关节炎发生的可能性
单中心队列纳入1023例银屑病患者,比较接受与未接受生物制剂者的银屑病关节炎发生风险。至少使用过一次生物制剂者银屑病关节炎患病率显著低于从未使用者(8.9% vs 26.1%,P<0.001),多因素分析证实生物制剂治疗与较低的外周型及中轴型银屑病关节炎发生可能性相关。
要点
- 至少使用过一次生物制剂者银屑病关节炎患病率为8.9%,从未使用者为26.1%(P<0.001)。
- 多因素分析中生物制剂治疗者银屑病关节炎发生可能性较低(adjOR 0.228,P<0.01)。
- TNF、IL-17及IL-23或12/23抑制剂均与较低的银屑病关节炎发生可能性相关(P<0.01)。
核心结论
- 本研究提供了一致且有意义的证据,支持不同类别生物制剂在降低外周型和中轴型银屑病关节炎发生可能性方面具有重要作用。
研究设计与样本
- 单中心队列研究,纳入1023例银屑病患者,进行风湿病学评估并记录临床与治疗数据。
- 采用卡方检验和多因素逻辑回归分析(校正主要银屑病关节炎危险因素),比较不同治疗组银屑病关节炎发生可能性。
主要发现
- 至少使用过一次生物制剂的银屑病患者银屑病关节炎患病率为8.9%,从未使用生物制剂者为26.1%(P<0.001)。
- 多因素分析中,全队列生物制剂治疗者银屑病关节炎发生可能性较低(adjOR 0.228,P<0.01)。
- 2005年后发病亚组adjOR 0.264,2014年后发病亚组adjOR 0.179,均P<0.01。
- TNF抑制剂adjOR 0.206,IL-17抑制剂adjOR 0.051,IL-23或12/23抑制剂adjOR 0.167,均P<0.01。
- 生物制剂治疗者纯外周型银屑病关节炎(adjOR 0.182)和外周型伴中轴受累银屑病关节炎(adjOR 0.115)患病率均较低(P<0.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the potential role of biologic treatment for psoriasis (PsO) in reducing the likelihood of psoriatic arthritis (PsA) development, through a detailed analysis that considered the different historical phases in PsA management, the different biologic classes and the different patterns of articular involvement. METHODS: A monocentric cohort of 1023 PsO patients underwent a rheumatological assessment in which clinical and therapeutic data were recorded. A chi-squared test and multivariate logistic regression analysis (adjusted for the main PsA risk factors) were performed to compare the likelihood of PsA development in different treatment groups. RESULTS: The PsA prevalence in PsO patients treated at least once with biologics was significantly lower than in patients never treated with biologics (8.9% vs 26.1%, P < 0.001). In multivariate analysis, a significantly (P < 0.01) lower likelihood of PsA development in biologic-treated patients was confirmed in the whole cohort (adjusted odds ratio [adjOR] 0.228), as well as in the subgroups of patients with PsO onset after 2005 (adjOR 0.264) and after 2014 (adjOR 0.179). Separately analysing the different biologic classes, the TNF (adjOR 0.206), IL-17 (adjOR 0.051) and IL-23 or 12/23 (adjOR 0.167) inhibitors were significantly (P < 0.01) associated with a lower likelihood of PsA development. Finally, patients treated with biologics had a significantly (P < 0.04) lower prevalence of both pure peripheral PsA (adjOR 0.182) and peripheral PsA with axial involvement (adjOR 0.115). CONCLUSIONS: This study provides meaningful and concordant evidence supporting the significant role of different classes of biologics in reducing the likelihood of peripheral and axial PsA development.
引用
- Floris A, Mugheddu C, Sichi L, et al. Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development. Rheumatology (Oxford). 2025. PMID: 38781521. doi:10.1093/rheumatology/keae257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。